Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Castaño JP[au]:

Search results

Items: 1 to 50 of 184

1.

Statins directly regulate pituitary cell function and exert antitumor effects in pituitary tumors.

Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, Venegas-Moreno E, L-López F, Fanciulli A, Moreno-Moreno P, Alhambra-Expósito MR, Barrera-Martín A, Dios E, Blanco-Acevedo C, Solivera J, Granata R, Kineman RD, Gahete MD, Soto-Moreno A, Gálvez-Moreno MA, Castaño JP, Luque RM.

Neuroendocrinology. 2020 Jan 15. doi: 10.1159/000505923. [Epub ahead of print]

PMID:
31940630
2.

Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.

Jiménez-Vacas JM, Herrero-Aguayo V, Montero-Hidalgo AJ, Gómez-Gómez E, Fuentes-Fayos AC, León-González AJ, Sáez-Martínez P, Alors-Pérez E, Pedraza-Arévalo S, González-Serrano T, Reyes O, Martínez-López A, Sánchez-Sánchez R, Ventura S, Yubero-Serrano EM, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM.

EBioMedicine. 2020 Jan;51:102547. doi: 10.1016/j.ebiom.2019.11.008. Epub 2020 Jan 3.

3.

Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer.

Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM.

J Clin Med. 2019 Nov 22;8(12). pii: E2056. doi: 10.3390/jcm8122056.

4.

A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary Tumors.

Vázquez-Borrego MC, Gupta V, Ibáñez-Costa A, Gahete MD, Venegas-Moreno E, Toledano-Delgado Á, Cano DA, Blanco-Acevedo C, Ortega-Salas R, Japón MA, Barrera-Martín A, Vasiljevic A, Hill J, Zhang S, Halem H, Solivera J, Raverot G, Gálvez MA, Soto-Moreno A, Paez-Pereda M, Culler MD, Castaño JP, Luque RM.

Clin Cancer Res. 2020 Feb 15;26(4):957-969. doi: 10.1158/1078-0432.CCR-19-2154. Epub 2019 Oct 17.

PMID:
31624102
5.

Metabolic Fingerprint of Acromegaly and its Potential Usefulness in Clinical Practice.

Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schätzlein M, Mesa J, Castaño JP, Luque RM, Simó R.

J Clin Med. 2019 Sep 26;8(10). pii: E1549. doi: 10.3390/jcm8101549.

6.

Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.

Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernández JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP, Luque RM.

Cancers (Basel). 2019 Sep 26;11(10). pii: E1439. doi: 10.3390/cancers11101439.

7.

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer.

Gómez-Gómez E, Jiménez-Vacas JM, Pedraza-Arévalo S, López-López F, Herrero-Aguayo V, Hormaechea-Agulla D, Valero-Rosa J, Ibáñez-Costa A, León-González AJ, Sánchez-Sánchez R, González-Serrano T, Requena-Tapia MJ, Castaño JP, Carrasco-Valiente J, Gahete MD, Luque RM.

J Clin Med. 2019 Sep 6;8(9). pii: E1400. doi: 10.3390/jcm8091400.

8.

Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.

Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-González AJ, Sáez-Martínez P, Alors-Pérez E, Fuentes-Fayos AC, Martínez-López A, Sánchez-Sánchez R, González-Serrano T, López-Ruiz DJ, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM.

Transl Res. 2019 Oct;212:89-103. doi: 10.1016/j.trsl.2019.07.001. Epub 2019 Jul 9.

PMID:
31344348
9.

Efficacy of the tryptophan hydroxylase inhibitor telotristat on growth and serotonin secretion in 2D and 3D cultured pancreatic neuroendocrine tumor cells.

Herrera-Martínez AD, Feelders RA, Van den Dungen R, Dogan-Oruc F, van Koetsveld PM, Castaño JP, de Herder W, Hofland LJ.

Neuroendocrinology. 2019 Jul 19. doi: 10.1159/000502200. [Epub ahead of print]

PMID:
31319410
10.

A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells.

Vázquez-Borrego MC, L-López F, Gálvez-Moreno MA, Fuentes-Fayos AC, Venegas-Moreno E, Herrera-Martínez AD, Blanco-Acevedo C, Solivera J, Landsman T, Gahete MD, Soto-Moreno A, Culler MD, Castaño JP, Luque RM.

Neuroendocrinology. 2020;110(1-2):70-82. doi: 10.1159/000500812. Epub 2019 Jul 5.

11.

Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells.

Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Gálvez Moreno MÁ, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ.

Horm Cancer. 2019 Jun;10(2-3):107-119. doi: 10.1007/s12672-019-00361-6. Epub 2019 May 18.

PMID:
31102172
12.

Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types.

Del Rio-Moreno M, Alors-Perez E, Borges de Souza P, Prados-Gonzalez ME, CastaÑo JP, Luque RM, Gahete MD.

Transl Res. 2019 Sep;211:147-160. doi: 10.1016/j.trsl.2019.02.013. Epub 2019 Mar 2.

PMID:
30904441
13.

Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease.

Del Río-Moreno M, Alors-Pérez E, González-Rubio S, Ferrín G, Reyes O, Rodríguez-Perálvarez M, Sánchez-Frías ME, Sánchez-Sánchez R, Ventura S, López-Miranda J, Kineman RD, de la Mata M, Castaño JP, Gahete MD, Luque RM.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3389-3402. doi: 10.1210/jc.2019-00021.

PMID:
30901032
14.

Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms.

Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, L-López F, Ibáñez-Costa A, Moreno-Moreno P, Alhambra-Expósito MR, Barrera-Martín A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Gálvez-Moreno MA, Castaño JP, Luque RM.

J Clin Endocrinol Metab. 2019 Aug 1;104(8):3501-3513. doi: 10.1210/jc.2019-00056.

PMID:
30860580
15.

E-cadherin expression is associated with somatostatin analogue response in acromegaly.

Venegas-Moreno E, Flores-Martinez A, Dios E, Vazquez-Borrego MC, Ibañez-Costa A, Madrazo-Atutxa A, Japón MA, Castaño JP, Luque RM, Cano DA, Soto-Moreno A.

J Cell Mol Med. 2019 May;23(5):3088-3096. doi: 10.1111/jcmm.13851. Epub 2019 Mar 6.

16.

Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.

Fuentes-Fayos AC, García-Martínez A, Herrera-Martínez AD, Jiménez-Vacas JM, Vázquez-Borrego MC, Castaño JP, Picó A, Gahete MD, Luque RM.

Minerva Endocrinol. 2019 Jun;44(2):109-128. doi: 10.23736/S0391-1977.19.02970-5. Epub 2019 Jan 16. Review.

PMID:
30650942
17.

Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers.

Herrera-Martínez AD, Hofland LJ, Gálvez Moreno MA, Castaño JP, de Herder WW, Feelders RA.

Endocr Relat Cancer. 2019 Mar 1;26(3):R157-R179. doi: 10.1530/ERC-18-0354. Review.

PMID:
30615596
18.

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives.

Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA.

Drugs. 2019 Jan;79(1):21-42. doi: 10.1007/s40265-018-1033-0. Review.

19.

Mouse models in endocrine tumors.

Gahete MD, Jimenez-Vacas JM, Alors-Perez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arevalo S, Castaño JP, Luque RM.

J Endocrinol. 2018 Nov 1. pii: JOE-18-0571.R1. doi: 10.1530/JOE-18-0571. [Epub ahead of print] Review.

PMID:
30475226
20.

Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study.

Gahete MD, Del Rio-Moreno M, Camargo A, Alcala-Diaz JF, Alors-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP, Lopez-Miranda J, Luque RM.

EBioMedicine. 2018 Nov;37:356-365. doi: 10.1016/j.ebiom.2018.10.056. Epub 2018 Nov 13.

21.

Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Novel Potential Biomarker in Gastroenteropancreatic Neuroendocrine Tumors.

Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Perez E, Pedraza-Arevalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM.

Clin Transl Gastroenterol. 2018 Oct 8;9(10):196. doi: 10.1038/s41424-018-0058-8.

22.

Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors.

Pedraza-Arévalo S, Gahete MD, Alors-Pérez E, Luque RM, Castaño JP.

Rev Endocr Metab Disord. 2018 Jun;19(2):179-192. doi: 10.1007/s11154-018-9465-0. Review.

PMID:
30293213
23.

Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?

Herrera-Martínez AD, Pedraza-Arevalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP, Luque RM.

J Clin Endocrinol Metab. 2019 Jan 1;104(1):57-73. doi: 10.1210/jc.2018-01455.

PMID:
30265346
24.

Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.

Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM.

J Cell Mol Med. 2018 Nov;22(11):5688-5697. doi: 10.1111/jcmm.13845. Epub 2018 Sep 6.

25.

International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S.

Pharmacol Rev. 2018 Oct;70(4):763-835. doi: 10.1124/pr.117.015388. Review.

26.

The Pituitary Gland is a Novel Major Site of Action of Metformin in Non-Human Primates: a Potential Path to Expand and Integrate Its Metabolic Actions.

Vázquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castaño JP, Kineman RD, Luque RM.

Cell Physiol Biochem. 2018;49(4):1444-1459. doi: 10.1159/000493448. Epub 2018 Sep 11.

27.

Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary Heart Disease Patients from the CORDIOPREV Study.

Jiménez-Lucena R, Rangel-Zúñiga OA, Alcalá-Díaz JF, López-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano EM, Caballero-Villarraso J, Delgado-Lista J, Castaño JP, Ordovás JM, Pérez-Martinez P, Camargo A, López-Miranda J.

Mol Ther Nucleic Acids. 2018 Sep 7;12:146-157. doi: 10.1016/j.omtn.2018.05.002. Epub 2018 May 8.

28.

Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas.

Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM.

Sci Rep. 2018 Apr 18;8(1):6173. doi: 10.1038/s41598-018-24260-y.

29.

Mediterranean Diet, Glucose Homeostasis, and Inflammasome Genetic Variants: The CORDIOPREV Study.

Roncero-Ramos I, Rangel-Zuñiga OA, Lopez-Moreno J, Alcala-Diaz JF, Perez-Martinez P, Jimenez-Lucena R, Castaño JP, Roche HM, Delgado-Lista J, Ordovas JM, Camargo A, Lopez-Miranda J.

Mol Nutr Food Res. 2018 May;62(9):e1700960. doi: 10.1002/mnfr.201700960. Epub 2018 Apr 20.

PMID:
29573224
30.

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines.

Rincón-Fernández D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castaño JP.

Carcinogenesis. 2018 Mar 8;39(3):447-457. doi: 10.1093/carcin/bgx146.

PMID:
29272342
31.

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly.

Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortés E, Madrazo-Atutxa A, Japón MA, Luque RM, Castaño JP, Cano DA, Soto-Moreno A.

J Cell Mol Med. 2018 Mar;22(3):1640-1649. doi: 10.1111/jcmm.13440. Epub 2017 Dec 21.

32.

Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: Lessons from human and non-human primate models.

Vázquez-Borrego MC, Gahete MD, Martínez-Fuentes AJ, Fuentes-Fayos AC, Castaño JP, Kineman RD, Luque RM.

Mol Cell Endocrinol. 2018 Mar 5;463:4-22. doi: 10.1016/j.mce.2017.12.007. Epub 2017 Dec 16. Review.

PMID:
29253530
33.

Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.

Herrera-Martínez AD, Gahete MD, Pedraza-Arevalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP.

Endocrine. 2018 Feb;59(2):426-437. doi: 10.1007/s12020-017-1482-3. Epub 2017 Dec 1.

PMID:
29196939
34.

Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients.

Luque RM, López-Sánchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM, Cara-García M, Álvarez-Benito M, López-Mirand A J, Gahete MD, Castaño JP.

Oncotarget. 2017 Aug 23;8(46):81462-81474. doi: 10.18632/oncotarget.20399. eCollection 2017 Oct 6.

35.

Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.

Pedraza-Arévalo S, Hormaechea-Agulla D, Gómez-Gómez E, Requena MJ, Selth LA, Gahete MD, Castaño JP, Luque RM.

Prostate. 2017 Nov;77(15):1499-1511. doi: 10.1002/pros.23426. Epub 2017 Sep 14.

PMID:
28905400
36.

The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.

Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM.

Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9.

37.

The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.

Hormaechea-Agulla D, Jiménez-Vacas JM, Gómez-Gómez E, L-López F, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sánchez-Sánchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibáñez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM.

FASEB J. 2017 Nov;31(11):4682-4696. doi: 10.1096/fj.201601264RRR. Epub 2017 Jul 13.

PMID:
28705809
38.

The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.

Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Salas RO, Serrano-Blanch R, Salvatierra Á, Hofland LJ, Luque RM, Gálvez-Moreno MA, Castaño JP.

Lung Cancer. 2017 Jul;109:128-136. doi: 10.1016/j.lungcan.2017.05.006. Epub 2017 May 13.

PMID:
28577942
39.

Metformin Reduces Prostate Tumor Growth, in a Diet-Dependent Manner, by Modulating Multiple Signaling Pathways.

Sarmento-Cabral A, L-López F, Gahete MD, Castaño JP, Luque RM.

Mol Cancer Res. 2017 Jul;15(7):862-874. doi: 10.1158/1541-7786.MCR-16-0493. Epub 2017 Apr 6.

40.

Adipokines (Leptin, Adiponectin, Resistin) Differentially Regulate All Hormonal Cell Types in Primary Anterior Pituitary Cell Cultures from Two Primate Species.

Sarmento-Cabral A, Peinado JR, Halliday LC, Malagon MM, Castaño JP, Kineman RD, Luque RM.

Sci Rep. 2017 Mar 6;7:43537. doi: 10.1038/srep43537.

41.

Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1.

L-López F, Sarmento-Cabral A, Herrero-Aguayo V, Gahete MD, Castaño JP, Luque RM.

J Cell Mol Med. 2017 Sep;21(9):1893-1904. doi: 10.1111/jcmm.13109. Epub 2017 Feb 28.

42.

BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas.

Ibáñez-Costa A, López-Sánchez LM, Gahete MD, Rivero-Cortés E, Vázquez-Borrego MC, Gálvez MA, de la Riva A, Venegas-Moreno E, Jiménez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japón MA, García-Arnés JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM.

Sci Rep. 2017 Feb 9;7:42002. doi: 10.1038/srep42002.

43.

Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism.

Ibáñez-Costa A, Luque RM, Castaño JP.

Growth Horm IGF Res. 2017 Apr;33:23-27. doi: 10.1016/j.ghir.2017.01.004. Epub 2017 Jan 22. Review.

PMID:
28157571
44.

Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial.

Moreno-Fernandez J, Gómez FJ, Gálvez Moreno MÁ, Castaño JP.

J Diabetes Res. 2016;2016:4171789. doi: 10.1155/2016/4171789. Epub 2016 Nov 29.

45.

Models of GH deficiency in animal studies.

Gahete MD, Luque RM, Castaño JP.

Best Pract Res Clin Endocrinol Metab. 2016 Dec;30(6):693-704. doi: 10.1016/j.beem.2016.11.001. Epub 2016 Nov 4. Review.

PMID:
27974185
46.

Obesity- and gender-dependent role of endogenous somatostatin and cortistatin in the regulation of endocrine and metabolic homeostasis in mice.

Luque RM, Cordoba-Chacon J, Pozo-Salas AI, Porteiro B, de Lecea L, Nogueiras R, Gahete MD, Castaño JP.

Sci Rep. 2016 Nov 30;6:37992. doi: 10.1038/srep37992.

47.

Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.

Hormaechea-Agulla D, Gómez-Gómez E, Ibáñez-Costa A, Carrasco-Valiente J, Rivero-Cortés E, L-López F, Pedraza-Arevalo S, Valero-Rosa J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Gahete MD, López-Miranda J, Requena MJ, Castaño JP, Luque RM.

Cancer Lett. 2016 Dec 1;383(1):125-134. doi: 10.1016/j.canlet.2016.09.022. Epub 2016 Sep 28.

PMID:
27693462
48.

Translational research in neuroendocrine tumors: pitfalls and opportunities.

Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP.

Oncogene. 2017 Apr 6;36(14):1899-1907. doi: 10.1038/onc.2016.316. Epub 2016 Sep 19. Review.

PMID:
27641330
49.

Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.

Ibáñez-Costa A, Rivero-Cortés E, Vázquez-Borrego MC, Gahete MD, Jiménez-Reina L, Venegas-Moreno E, de la Riva A, Arráez MÁ, González-Molero I, Schmid HA, Maraver-Selfa S, Gavilán-Villarejo I, García-Arnés JA, Japón MA, Soto-Moreno A, Gálvez MA, Luque RM, Castaño JP.

J Endocrinol. 2016 Nov;231(2):135-145. Epub 2016 Sep 1.

PMID:
27587848
50.

Serum Galanin Levels in Young Healthy Lean and Obese Non-Diabetic Men during an Oral Glucose Tolerance Test.

Sandoval-Alzate HF, Agudelo-Zapata Y, González-Clavijo AM, Poveda NE, Espinel-Pachón CF, Escamilla-Castro JA, Márquez-Julio HL, Alvarado-Quintero H, Rojas-Rodríguez FG, Arteaga-Díaz JM, Eslava-Schmalbach JH, Garcés-Gutiérrez MF, Vrontakis M, Castaño JP, Luque RM, Diéguez C, Nogueiras R, Caminos JE.

Sci Rep. 2016 Aug 23;6:31661. doi: 10.1038/srep31661.

Supplemental Content

Loading ...
Support Center